J Korean Med Assoc.  2010 Mar;53(3):204-207. 10.5124/jkma.2010.53.3.204.

Treatment of Dyslipidmia

• Sung JD

• KMID: 1775331
• DOI: http://doi.org/10.5124/jkma.2010.53.3.204

Abstract

Treatment of dyslipidemia is apparently one of the most important measures for prevention of atherosclerotic cardiovascular diseases. Recent trend reflecting several study results after publication of the ATP-III guideline in 2001 recommends more aggressive target LDL goals in very high risk patients. On the other hand, public health approaches, such as life style modification, to low risk group should not be neglected for primary prevention to avoid life-long medication in undesirably large number of people. Intensity of the treatment must be adjusted after a careful consideration of each patient's global risk, not just by lipid level alone. More attention to dyslipidemia management is needed for both clinical and public health perspectives.

Keyword

Dyslipidemia; Coronary artery disease; Prevention

MeSH Terms

Cardiovascular Diseases
Coronary Artery Disease
Dyslipidemias
Hand
Humans
Life Style
Primary Prevention
Public Health
Publications

Reference

1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998. 97:1837–1847.

2. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). Jama. 1986. 256:2823–2828.

3. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. Jama. 1995. 274:131–136.

4. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. Bmj. 1991. 303:276–282.

5. Wakugami K, Iseki K, Kimura Y, Okumura K, Ikemiya Y, Muratani H, Fukiyama K. Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened co-hort in Okinawa, Japan. Jpn Circ J. 1998. 62:7–14.

6. Jee SH, Song JW, Cho HK, Kim S, Jang Y, Kim JH. Development of the individualized health risk appraisal model of ischemic heart disease risk in Korea. Korean Journal of Lipidology. 2004. 14:153–169.

7. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002. 106:3143–3421.

8. Miller M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004. 351:714–717. author reply-7.

9. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003. 361:1149–1158.

10. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002. 360:1623–1630.

11. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003. 361:2005–2016.

12. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004. 110:227–239.

13. Sung J, Kim SH, Kim Y-D, Baek SH, Ahn Y, Lim DS, Cho HK, Chae SC, Han KH, Kim H-S. Ten centers' study on the present state of treatment for hypercholesterolemia in patients with coronary artery disease. Korean J Med. 2005. 69:371–378.

14. Wang TJ, Larson MG, Levy D, Benjamin EJ, Kupka MJ, Manning WJ, Clouse ME, D'Agostino RB, Wilson PW, O'Donnell CJ. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation. 2002. 106:1189–1191.